Executive Appointment - Pamela Spikner has been appointed as Senior Vice President, Chief Accounting Officer, and Controller at BD, effective January 20 [1][2] - Spikner will oversee all accounting policy and financial reporting for the company, reporting to Chris DelOrefice, Executive Vice President and Chief Financial Officer [2] Professional Background - Spikner brings over 25 years of expertise in corporate finance and accounting, with a strong track record in leadership and team building [1] - Prior to joining BD, Spikner served as Chief Accounting Officer at R1 RCM, Inc, where she managed financial reporting, compliance, and operational efficiency programs [1] - She held various accounting leadership roles at Exelon Corporation, a Fortune 200 company, and served as Assistant Corporate Controller at Hill-Rom Holdings, Inc [1] - Spikner began her career in the audit practice of PwC, working with clients in the healthcare and insurance industries [1] Education and Certifications - Spikner holds a Bachelor of Science in Accounting from Indiana University of Pennsylvania [5] - She is a Certified Public Accountant (CPA) and a Certified Internal Auditor (CIA) [5] Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery [3] - The company employs over 70,000 people and operates in virtually every country, partnering with organizations to address global health challenges [3] - BD develops innovative technologies and solutions to enhance clinical therapy, improve safety, and increase efficiency in healthcare delivery [3]

Survey Findings - 72% of women in the US have delayed gynecology visits, with 54% citing fear or discomfort and 49% citing scheduling challenges as reasons [1][2][3] - 50% of women are unaware of how often they should be screened for cervical cancer [2][3] - 81% of women want more comfortable and less invasive HPV/cervical cancer testing options compared to pelvic exams [5] - 73% of women are interested in using self-collection vaginal swab tests at the doctor's office, and 74% are interested in self-collection at home [5] - 66% of women are knowledgeable about HPV, but 88% are unaware that Pap tests are not the most accurate for detecting cervical cancer, and 81% are unaware that women aged 30-65 do not need annual screenings [6] Industry Trends and Recommendations - Self-collection of vaginal samples is seen as a critical step forward in cervical cancer screening, reducing discomfort and time associated with pelvic exams [4] - Guidelines from organizations like WHO, ACS, ASCCP, and the US Preventive Services Task Force recommend self-collection for HPV screening and tests that identify more individual types of HPV [8] - The WHO aims to eliminate cervical cancer as a public health issue by 2030, emphasizing the importance of regular screening [9] Company Innovation - BD's Onclarity™ HPV Assay is FDA-approved for self-collection and identifies more individual high-risk types of HPV than any other test, enabling better tracking and management of high-risk cases [7] - BD is advancing health through innovative technology, diagnostics, and care delivery, with a focus on improving safety, efficiency, and access to healthcare [12]

FRANKLIN LAKES, N.J., Jan. 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host its virtual 2025 Annual Meeting of Shareholders (the "Annual Meeting") on Tuesday, January 28, 2025, at 1:00 p.m. (ET).As described in the proxy materials for the Annual Meeting previously distributed, shareholders as of the close of business on December 9, 2024, or their duly authorized proxies, will be able to attend and participa ...

Becton, Dickinson and Company (BDX) , popularly known as BD, is well-poised for growth in the coming quarters, courtesy of its solid product portfolio. The optimism led by a solid fourth-quarter fiscal 2024 performance and a few strategic deals are expected to contribute further. However, macroeconomic concerns and stiff competition persist.Over the past year, this Zacks Rank #3 (Hold) stock has lost 6.9% against the 0.3% rise of the industry and the S&P 500’s 26% growth.The renowned medical technology comp ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...

Becton, Dickinson and Company (BDX) , popularly known as BD, and Babson Diagnostics announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings. The commercial partnership is an expansion of BD and Babson's collaboration to advance capillary blood testing, which began in 2016 and has since evolved into a strategic partnership.The blood testing pr ...

FRANKLIN LAKES, N.J. and AUSTIN, Texas, Dec. 17, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, today announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings. BD and Babson Diagnostics today launched th ...

FRANKLIN LAKES, N.J., Dec. 16, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement:BD has reached an agreement with the U.S. Securities and Exchange Commission (SEC) to resolve the previously disclosed investigation related to prior public disclosures and SEC reporting regarding the BD Alaris™ System, which was acquired by BD from CareFusion in 2015 and is part of the BD Medication Management Solutions busines ...

The Zacks Medical - Dental Supplies industry in the Medical sector has shown a consolidating trend in 2024 amid a rise in product sales. Although dental patient traffic remained stable during the third quarter, discretionary spending declined on higher-cost dental procedures, affecting consumables demand. Broader macroeconomic challenges like inflation and interest rates have constrained budgets for dental practices.The pricing environment has stabilized, but it created a lag in this segment’s recovery. Per ...

Summary of Becton, Dickinson and Company (BDX) Conference Call Company Overview - **Company**: Becton, Dickinson and Company (NYSE: BDX) - **Date**: December 3, 2024 - **Participants**: - Richard Byrd - EVP and President of Interventional Business - Chris DelOrefice - Executive Vice President & Chief Financial Officer - Vijay Kumar - Evercore ISI Key Points Financial Performance - **Fiscal Year 2024 Growth**: Achieved strong overall growth of 5% despite market dynamics affecting certain segments [4][10] - **Segment Performance**: - BDB and pharma systems grew low single digits (1%) - Other portfolio segments, excluding a low single-digit decline in China, grew nearly 6% [5][6] - **Fiscal Year 2025 Guidance**: - Projected organic growth of 4% to 4.5%, with expectations of continued challenges in China [6][10] - Anticipated earnings growth of approximately 10% at the midpoint [10] - **Gross Margin Improvement**: Expected to improve by about 100 basis points in FY 2025, driven by strong second-half performance in FY 2024 [7][10] Cash Flow and Share Buybacks - **Cash Conversion**: Strong cash conversion rate of 82% in FY 2024, expected to remain similar in FY 2025 [8][10] - **Share Buybacks**: Plans to execute approximately $1 billion in share repurchases throughout FY 2025 [10][88] Market Dynamics and Challenges - **China Market**: Anticipated mid-single-digit decline in China due to market dynamics and volume-based procurement [25][34] - **Macro Environment**: Positive outlook for med tech utilization in healthcare systems, with BD well-positioned to benefit [12][14] - **Tariffs and Supply Chain**: Monitoring potential tariff impacts, particularly concerning manufacturing hubs in Mexico and China [15][16][18] Product and Segment Insights - **Interventional Business**: Strong performance driven by the PureWick franchise, addressing urinary incontinence in both acute and home care settings [36][38] - **Surgical Segment**: Notable growth in hemostat sealants and hernia meshes, with a focus on innovative products like Phasix [46][50] - **Biosciences and Pharma Systems**: - Biosciences expected to recover with strong growth potential in clinical applications [56][62] - Pharma systems, particularly biologics, projected to return to high single-digit to double-digit growth [60][62] Future Outlook - **Investor Day**: Upcoming event to provide further insights into growth strategies and product innovations [53][79] - **Long-term Growth**: BD aims to position PureWick as a $1 billion franchise by 2030, with ongoing expansion into international markets [42][53] Additional Considerations - **Regulatory Environment**: BD has been proactive in addressing quality system improvements and regulatory compliance, particularly concerning its dispensing business [72][74] - **Tax Rate**: Expected increase in tax rate to approximately 14.75% for FY 2025, influenced by global minimum tax regulations [86] This summary encapsulates the key insights and financial outlook for Becton, Dickinson and Company as discussed in the conference call, highlighting both opportunities and challenges in the current market landscape.